{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T12:49:01Z","timestamp":1702298941118},"reference-count":64,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The BCR-ABL-negative myeloproliferative neoplasms (MPNs) are clonal stem cell derived malignancies, which include polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF). The MPNs are characterized by dysregulated JAK-STAT signaling pathways. PV and ET are associated with an increased risk of thrombo-hemorrhagic complications, risk of progression to MF and leukemia. Presentation of patients with PV and ET is variable and usually as a result of abnormal full blood count indices (raised hemoglobin and hematocrit, leukocytosis, and thrombocytosis). Presentation with thrombosis or splenomegaly occurs in \u223c30% of patients. Historically thought of as indolent compared with MF, patients with PV and ET have significant disease symptom burden which does not directly correlate to the current clinical prognostic classifications. The mainstay of therapy is reserved for patients with high-risk disease and thus excludes a population of patients with significant symptom related morbidity impacting their quality-of-life and survival. Recent treatment strategies have aimed to incorporate disease burden assessment into the selection of therapeutic interventions such as JAK2 inhibitors and HDAC inhibitors. We will review the advances in the field of MPN symptom assessment and symptom burden experienced by ET and PV patients. We will also discuss the risk-stratified management of ET and PV patients alongside symptom assessment and the impact of potential novel therapies, for patients who fail to respond to conventional treatment.<\/jats:p>","DOI":"10.1182\/asheducation-2015.1.340","type":"journal-article","created":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T15:23:25Z","timestamp":1473953005000},"page":"340-348","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Management of symptoms in polycythemia vera and essential thrombocythemia patients"],"prefix":"10.1182","volume":"2015","author":[{"given":"Deepti","family":"Radia","sequence":"first","affiliation":[{"name":"Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UK; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly L.","family":"Geyer","sequence":"additional","affiliation":[{"name":"Division of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111702534461100_B1","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2019111702534461100_B2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organisation (WHO) classification of myeloid neoplasms and acute leukaemia; rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"25","key":"2019111702534461100_B3","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulun in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111702534461100_B4","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"20","key":"2019111702534461100_B5","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","article-title":"Clinical utility of routine MPL exon 10 mutations in the diagnosis of essential thrombocythaemia and primary myelofibrosis","volume":"149","author":"Boyd","year":"2010","journal-title":"Br J Haematol"},{"issue":"26","key":"2019111702534461100_B6","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Porgnostic Score of thrombosis in World Health Organisation- essential thrmobocythaemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2019111702534461100_B7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ajh.23417","article-title":"Polycythaemia vera and essential thrombocythaemia: 2013 update on diagnosis, risk stratification and management","volume":"88","author":"Tefferi","year":"2013","journal-title":"Am J Haematol"},{"key":"2019111702534461100_B8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ajh.23895","article-title":"Polycythaemia vera and essential thrombocythaemia: 2015 update on diagnosis, risk stratification and management","volume":"90","author":"Tefferi","year":"2015","journal-title":"Am J Haematol"},{"issue":"21","key":"2019111702534461100_B9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood.V124.21.632.632","article-title":"Risk of arterial and venous thrombosis in 11,155 patients with myeloproliferative neoplasms and 44,620 matched controls: a population-based study","volume":"124","author":"Hultcrantz","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111702534461100_B10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000204873","article-title":"Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients","volume":"85","author":"Cervantes","year":"1991","journal-title":"Acta Haematologica"},{"issue":"3","key":"2019111702534461100_B11","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/10428194.2013.813500","article-title":"Epidemiology of myeloproliferative neoplasms (MPN) in the United States","volume":"55","author":"Mehta","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111702534461100_B12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythaemia and ploycythaemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"issue":"1","key":"2019111702534461100_B13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"key":"2019111702534461100_B14","first-page":"13","article-title":"The Functional Assessment of Cancer Therapy-Anaemia (FACT-An) Scale; a new tool for the assessment of outcomes in cancer anaemia and fatigue","volume":"34","author":"Cella","year":"1997","journal-title":"Semin Hematol"},{"issue":"5","key":"2019111702534461100_B15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","article-title":"The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatugue Inventory","volume":"85","author":"Mendoza","year":"1999","journal-title":"Cancer"},{"issue":"1","key":"2019111702534461100_B16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/028418602317314064","article-title":"Symptoms, symptoms distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatemtn with interferon-alpha","volume":"41","author":"Merup","year":"2002","journal-title":"Acta Oncol"},{"issue":"11","key":"2019111702534461100_B17","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/cncr.21900","article-title":"A phase II trial of interferon alpha -2b therapy for polycythaemia vera and essential thrombocythaemia: feasibility, clinical and biological effects, and impact on quality of life","volume":"106","author":"Samuelsson","year":"2006","journal-title":"Cancer"},{"issue":"9","key":"2019111702534461100_B18","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk Res"},{"issue":"2","key":"2019111702534461100_B19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2019111702534461100_B20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111702534461100_B21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"33","key":"2019111702534461100_B22","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111702534461100_B23","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1182\/blood.V124.21.3168.3168","article-title":"The efficacy and safety of continued hydroxyurea therapy versus switching to ruxolitinib in patients with polycythemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)","volume":"124","author":"Mesa","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2019111702534461100_B24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukaemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"issue":"24","key":"2019111702534461100_B25","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","article-title":"Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients","volume":"123","author":"Geyer","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111702534461100_B26","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood.V124.21.3183.3183","article-title":"Impact of Myeloproliferative Neoplasms (MPNs) on Patients' Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States","volume":"124","author":"Mesa","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111702534461100_B27","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood.V124.21.1862.1862","article-title":"The impact of medical comorbidities in MPN-related fatigue","volume":"124","author":"Scherber","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111702534461100_B28","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood.V124.21.3173.3173","article-title":"High prevalence of mood disorders in MPNs and their possible role in MPN related fatigue","volume":"124","author":"Scherber","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111702534461100_B29","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1182\/blood.V122.21.4074.4074","article-title":"Cytokine profile changes in 309 myelofibrosis patients: comparison of JAK1\/JAK2 inhibitor therapy vs. placebo: correlative analysis from the Comfort-I trial","volume":"122","author":"Dueck","year":"2013","journal-title":"Blood"},{"key":"2019111702534461100_B30","article-title":"Gender differences and MPN symptom burden: an analysis by the MPN quality of life international study group (MPN-QOL ISG)","author":"Geyer","year":"2014","journal-title":"European Hematology Association Annual Meeting Abstracts"},{"issue":"21","key":"2019111702534461100_B31","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1182\/blood.V122.21.4087.4087","article-title":"Insomnia, quality of life and MPN symptom burden: an analysis by the MPN Quality Of Life International Study Group (MPN-QOL ISG)","volume":"122","author":"Geyer","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111702534461100_B32","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1182\/blood.V122.21.4088.4088","article-title":"Sexuality challenges, intimacy, and MPN symptom burden: an analysis by the MPN Quality Of Life International Study Group (MPN-QOL ISG)","volume":"122","author":"Geyer","year":"2013","journal-title":"Blood"},{"issue":"21","key":"2019111702534461100_B33","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1182\/blood.V122.21.4067.4067","article-title":"Myeloproliferative (MPN) symptom burden response thresholds: assessment of MPN-SAF TSS quartiles as potential markers of symptom response","volume":"122","author":"Emanuel","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2019111702534461100_B34","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/onc.2010.479","article-title":"Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythaemia vera and contribute to the growth of clonal erthroblasts independently of JAK2V617F","volume":"30","author":"Boissinot","year":"2011","journal-title":"Oncogene"},{"issue":"5","key":"2019111702534461100_B35","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythaemia cera and essential thrombocythaemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","journal-title":"Exp Hematol"},{"issue":"3","key":"2019111702534461100_B36","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bbi.2006.08.001","article-title":"Inflammatory responses to psychological stress in fatigued breast cancer survivors; relationship to glucocorticoids","volume":"21","author":"Bower","year":"2007","journal-title":"Brain Behaviour Immun"},{"key":"2019111702534461100_B37","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/1097-0142(20010915)92:6+<1684::AID-CNCR1497>3.0.CO;2-Z","article-title":"The role of cytokines in cancer-related fatigue","volume":"92","author":"Kurzock","year":"2001","journal-title":"Cancer"},{"issue":"4","key":"2019111702534461100_B38","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/cncr.21234","article-title":"Cognitive impairment, fatigue and cytokine levels in patients with acute myekogenous leukaemia or myledysplastic syndrome","volume":"104","author":"Meyers","year":"2005","journal-title":"Cancer"},{"issue":"4","key":"2019111702534461100_B39","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.21671","article-title":"Fatogue in long-term breast carcinoma survivors; a longitudinal investigation","volume":"106","author":"Bower","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"2019111702534461100_B40","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin(IL)-8,IL-2R,IL-12 and IL-15 levels are independently porgnostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111702534461100_B41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.2010.031070","article-title":"Inflammation and thrombosis in essential thrombocythemia and polycythaemia vera: different role of C-reactive protein and pentraxin 3","volume":"96","author":"Barbui","year":"2011","journal-title":"Haematologica"},{"issue":"24","key":"2019111702534461100_B42","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2011-04-348144","article-title":"TNF\u03b1 facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms","volume":"118","author":"Fleischman","year":"2011","journal-title":"Blood"},{"issue":"21","key":"2019111702534461100_B43","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1182\/blood.V122.21.4070.4070","article-title":"The relationship between cytokine levels and symptoms in patients with myelofibosis (MF) from COMFORT-II, a phase 3 study of ruxolitinib (RUX) vs best availabletherapy (BAT)","volume":"122","author":"Squires","year":"2013","journal-title":"Blood"},{"key":"2019111702534461100_B44","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for ploycythaemia vera and essential thrmobcythaemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111702534461100_B45","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111702534461100_B46","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"2019111702534461100_B47","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood.V122.21.1595.1595","article-title":"The MPN fatigue project: stage 1 results of the MPN forum internet-based survey among 879 MPN Patients","volume":"122","author":"Emanuel","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2019111702534461100_B48","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3324\/haematol.2009.007047","article-title":"The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera","volume":"94","author":"Pieri","year":"2009","journal-title":"Haematologica"},{"issue":"9","key":"2019111702534461100_B49","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/leu.2009.85","article-title":"Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms","volume":"23","author":"Wang","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"2019111702534461100_B50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2133.1987.tb05787.x","article-title":"Skin mast cells in polycythaemia vera: relationship to the pathogenesis and treatment of pruritis","volume":"116","author":"Jackson","year":"1987","journal-title":"Br J Dermatol"},{"issue":"8","key":"2019111702534461100_B51","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/ajh.23474","article-title":"Aquagenic pruritis in polycythaemia vera: characteristics and influence on quality of life in 441 patients","volume":"88","author":"Siegal","year":"2013","journal-title":"Am J Hematol"},{"issue":"10","key":"2019111702534461100_B52","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(12)70373-X","article-title":"Aprepitant for management of severe pruritis related to biological cancer treatments: a pilot study","volume":"13","author":"Santini","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111702534461100_B53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1365-2141.2001.03092.x","article-title":"Endothelial dysfunction in patients with polycythaemia vera","volume":"115","author":"Neunteufl","year":"2001","journal-title":"Br J Haematol"},{"issue":"Issue 4","key":"2019111702534461100_B54","article-title":"Antiplatelet drugs for preventing arterial and venous thrombotic events in patients with polycythaemia vera and essential thrombocythaemia","author":"Squizzato","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"2019111702534461100_B55","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythaemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111702534461100_B56","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythaemia","volume":"116","author":"Alvarez-Larran","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111702534461100_B57","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111702534461100_B58","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/leu.2010.120","article-title":"Clonal analysis of erythroid progenitors suggests that pegylated alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells","volume":"24","author":"Kilagjjan","year":"2010","journal-title":"Leukaemia"},{"issue":"10","key":"2019111702534461100_B59","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","article-title":"Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients","volume":"979","author":"Gowin","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"2019111702534461100_B60","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1365-2141.2010.08430.x","article-title":"Clinical evaluation of the European LeukameaNet criteria for clinicohaematological response and resistance\/intolerance to hydroxycarbamide in essential thrombocythaemia","volume":"152","author":"Hernandez-Boluda","year":"2011","journal-title":"Br J Haematol"},{"issue":"5","key":"2019111702534461100_B61","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythaemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111702534461100_B62","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V124.21.1848.1848","article-title":"Symptom severity and clinical variables of polycythemia vera patients with splenomegaly, phlebotomy requirements and\/or hydroxyurea use: a retrospective evaluation of 1334 patients","volume":"124","author":"Geyer","year":"2014","journal-title":"Blood"},{"issue":"21","key":"2019111702534461100_B63","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2015-01-624536","article-title":"JAK2V617F complete molecular remission in polycythaemia vera\/essential thrombocythaemia patients treated with ruxolitinib","volume":"125","author":"Pieri","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2019111702534461100_B64","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1403141","article-title":"Two clinical phenotypes in polycythemia vera","volume":"371","author":"Spivak","year":"2014","journal-title":"N Engl J Med"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/340\/1250012\/bep00115000340.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2015\/1\/340\/1250012\/bep00115000340.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T07:54:04Z","timestamp":1573977244000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2015\/1\/340\/20648\/Management-of-symptoms-in-polycythemia-vera-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,5]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2015.1.340","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,5]]}}}